A step towards a HER2-positive breast cancer super family
Mené sur 719 patientes atteintes d'un cancer du sein HER2+ de stade avancé, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'évérolimus à un traitement de première ligne combinant trastuzumab et paclitaxel
The BOLERO-1 study, reported in The Lancet Oncology, is the second attempt to establish the role of an mTOR inhibitor in patients with HER2-positive metastatic breast cancer. The study was based on findings that mTOR inhibition sensitises PTEN-deficient tumours to trastuzumab. Therefore, simultaneous treatment with the mTOR inhibitor everolimus and trastuzumab could increase the population of p atients benefiting from trastuzumab as treatment for their newly diagnosed metastatic disease. Researchers noted that although there was no benefit from adding everolimus to trastuzumab for the overall population, a clinically (although not statistically) significant benefit was noted for women with hormone receptor (HR)-negative disease.
The Lancet Oncology , commentaire, 2014